Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
The stock's performance was ahead of the S&P 500's daily gain of 0.09%. Elsewhere, the Dow saw a downswing of 0.1%, while the tech-heavy Nasdaq appreciated by 0.16%. The biotechnology company's shares have seen an increase of 1.97% over the last month, not keeping up with the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83%. The upcoming earnings release of Recursion Pharmaceuticals will be of great interest to investors. On that day, Recursion Pharmaceuticals is projected to report earnings of -$0.41 per share, which would represent a year-over-year decline of 7.89%. In the meantime, our current consensus estimate forecasts the revenue to be $15.98 million, indicating a 45.01% growth compared to the corresponding quarter of the prior year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.60 per share and revenue of $45.99 million. These totals would mark changes of -1.27% and +3.18%, respectively, from last year
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Recursion Announces Pricing of $200 Million Public Offering of Class A Common StockGlobeNewswire
- Recursion Announces Proposed Offering of Class A Common StockGlobeNewswire
- Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $17.00 price target on the stock.MarketBeat
- Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data [Yahoo! Finance]Yahoo! Finance
- Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic DataBusiness Wire
RXRX
Earnings
- 5/9/24 - Beat
RXRX
Sec Filings
- 6/28/24 - Form 4
- 6/27/24 - Form 4
- 6/27/24 - Form 144
- RXRX's page on the SEC website